How can transverse myelitis be differentiated from other forms of paralysis such as chronic inflammatory demyelinating polyneuropathy (CIDP)?

Differentiating Transverse Myelitis from CIDP

Transverse myelitis and CIDP are fundamentally distinguished by their anatomical location: transverse myelitis affects the central nervous system (spinal cord) while CIDP affects the peripheral nervous system (nerve roots and peripheral nerves), requiring different diagnostic approaches centered on MRI for the former and nerve conduction studies for the latter.

Key Clinical Distinctions

Timing and Progression

• Transverse myelitis: Typically reaches maximum deficit within hours to days (often within 6 hours for acute presentations) 1
• CIDP: Progressive course evolving over 8 weeks or more 2, 3

Neurological Pattern

Transverse myelitis presents with:

• Thoracic banding dysesthesia 4
• Upper motor neuron signs (hyperreflexia, spasticity)
• Sensory level corresponding to spinal cord segment
• Autonomic dysfunction (bladder/bowel involvement)
• Bilateral symptoms below the lesion level

CIDP presents with:

• Progressive proximal AND distal weakness in upper and lower extremities 3
• Reduced or absent reflexes (lower motor neuron pattern) 3
• Sensory loss without a clear spinal level
• Typically no autonomic involvement (absent autonomic involvement favors CIDP with OR 17.82) 2
• Absent muscle atrophy initially (OR 16.65 for CIDP) 2

Diagnostic Algorithm

Step 1: Clinical Red Flags

Look for these features that strongly suggest transverse myelitis over CIDP:

• Symptom progression to nadir < 6 hours 1
• Presence of autonomic dysfunction
• Clear sensory level
• Hyperreflexia or Babinski sign
• Muscle atrophy (suggests peripheral process)

Step 2: Primary Imaging

MRI of the spine with and without contrast is the definitive test for transverse myelitis 5, 6:

Transverse myelitis patterns:

• Longitudinal extensive transverse myelitis (LETM): extends ≥3 vertebral segments 6, 7
• Short segment lesions: ovoid or peripheral, often MS-related 6, 7
• Linear or eccentric lesions on sagittal T2 (the "eccentric sign") 1
• Patchy and fusiform appearance 1
• Central cord involvement with T2 hyperintensity
• Enhancement patterns indicating blood-cord barrier breakdown 5

CIDP shows:

• Normal spinal cord imaging 5
• Possible nerve root enhancement (though this requires specific imaging protocols)

Step 3: Electrophysiological Testing

Nerve conduction studies are diagnostic for CIDP 8, 2:

CIDP criteria (EAN/PNS 2021):

• Ulnar motor conduction velocity < 35.7 m/s (OR 5.21) 2
• Ulnar motor conduction block (OR 13.37) 2
• Demyelinating features: prolonged distal latencies, conduction velocity slowing, temporal dispersion
• Must fulfill electrodiagnostic criteria for demyelination 9

Transverse myelitis:

• Normal peripheral nerve conduction studies
• Somatosensory evoked potentials may show central conduction delays

Step 4: Ancillary Testing

For transverse myelitis:

• CSF analysis: pleocytosis, elevated protein, oligoclonal bands (especially if MS-related) 9
• Aquaporin-4 antibodies (neuromyelitis optica spectrum disorder) 7
• MOG antibodies
• Brain MRI mandatory to assess for demyelinating disease, systemic autoimmune, infectious, or paraneoplastic causes 6, 7

For CIDP:

• Nerve ultrasound: multifocal nerve enlargement 9
• Skin biopsy may show reduced intraepidermal nerve fiber density 8
• CSF: elevated protein without pleocytosis (albuminocytologic dissociation)
• No oligoclonal bands (these suggest central demyelination) 9

Critical Pitfalls to Avoid

1. Concurrent disease exists: Rare cases of combined central and peripheral demyelination (CCPD) can occur, presenting with features of both 4, 9. If clinical features don't align, perform both MRI and nerve conduction studies.

2. Early MS can mimic CIDP: Short segment transverse myelitis is often the first presentation of MS 6, 7. Always obtain brain MRI.

3. Spinal cord infarction mimics acute transverse myelitis: Both can present with rapid onset, but infarction typically reaches nadir within 1 hour and shows restricted diffusion on DWI/ADC sequences 7, 1.

4. Autonomic testing has limited specificity: While autonomic dysfunction suggests transverse myelitis, autonomic testing is only Level C evidence for small fiber neuropathy diagnosis 8 and should not be the primary differentiating tool.

Treatment Implications

The distinction is critical because treatments differ fundamentally:

• Transverse myelitis: High-dose IV methylprednisolone is first-line 4
• CIDP: IVIG, plasmapheresis, or corticosteroids; targeted therapies emerging 3
• Misdiagnosis leads to inappropriate IVIG use in non-CIDP patients 2

When probability of CIDP is < 92% on clinical-electrophysiological assessment, CIDP is unlikely and alternative diagnoses including transverse myelitis should be strongly considered 2.